A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells

Area of Science:

• Immunology
• Cell Biology
• Biotechnology

Background:

• Adoptive T cell therapy requires enhanced in vivo proliferation and function.
• The CD28 costimulatory pathway is crucial for T cell activation but has restricted ligand expression.
• Limited ligand availability for CD28 hinders effective T cell responses in immunotherapy.

Purpose of the Study:

• To develop a chimeric receptor that leverages the widely expressed CD2 ligand to activate the CD28 signaling pathway.
• To assess the functionality of this novel CD2/CD28 chimeric receptor in T cells.
• To evaluate its potential utility in adoptive immunotherapy strategies.

Main Methods:

• Generation of a chimeric receptor combining CD28 signaling domains with the CD2 extracellular domain.
• Retroviral transduction of CTLL.2 cells with the CD2/CD28 chimeric receptor.
• Confirmation of cell surface expression and assessment of CD28 signaling pathway activation via CD2 cross-linking.

Main Results:

• The CD2/CD28 chimeric receptor was successfully expressed on the surface of CTLL.2 cells.
• Cross-linking of CD2 on cells expressing the chimeric receptor triggered downstream CD28 signaling.
• The engineered receptor effectively activated the CD28 pathway, indicating functional potential.

Conclusions:

• The CD2/CD28 chimeric receptor offers a promising strategy to enhance T cell function by utilizing the CD2 pathway.
• This approach may overcome limitations associated with restricted CD28 ligand expression in adoptive immunotherapy.
• Further investigation into the utility of this chimeric receptor for enhancing adoptive immunotherapy is warranted.